| Entry |
|
|---|
| Name |
Tozinameran (JAN);
Comirnaty (TN) |
|---|
| Remark |
|
|---|
| Efficacy |
Active immunization (SARS-CoV-2) |
|---|
| Comment |
Tozinameran is mRNA encoding full length of spike protein analog of SARS-CoV-2
|
|---|
| Target |
Severe acute respiratory syndrome coronavirus 2 spike glycoprotein [KO: K24152] |
|---|
| Pathway |
| ko05171 | Coronavirus disease - COVID-19 |
|
|---|
| Brite |
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11971
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11971
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
